Dysthyroid optic neuropathy (DON) is a severe, vision-threatening manifestation of thyroid eye disease. We conducted a retrospective descriptive case series of consecutive patients with DON treated with teprotumumab at a single center to evaluate functional, structural, magnetic resonance imaging (MRI)-based inflammatory, and safety outcomes. Six patients (10 eyes) were included....
✦ The floor
Discussion
Signed responses from readers of the wire.
No actionable change for audiologists — teprotumumab targets dysthyroid optic neuropathy, a vision complication of thyroid eye disease, and this retrospective case series has no direct bearing on audiology practice.
Thyroid disorders intersect with audiology through ototoxicity (hearing damage from medications) and autoimmune hearing loss; understanding emerging systemic treatments for thyroid disease broadens the clinical context audiologists may encounter in shared patients.
- 01Teprotumumab showed early functional and structural improvements in dysthyroid optic neuropathy (sight-threatening thyroid eye disease).
- 02Study design is retrospective case series — lowest tier of clinical evidence.
- 03Primary relevance is to ophthalmology/endocrinology, not audiology directly.
- 04Thyroid disease is a known risk factor for sensorineural hearing loss, making systemic treatment outcomes broadly relevant.
- 05Published in Endocrine Journal (DOI 10.1507/endocrj.EJ26-0321).
Teprotumumab produces early functional and structural improvement in patients with dysthyroid optic neuropathy.
studypartially supported- PMID
- 42749636
- DOI
- 10.1507/endocrj.EJ26-0321.
- Journal
- Endocrine Journal
- Publication type
- case_report
- Evidence level
- 4
- Population
- Patients with dysthyroid optic neuropathy as a severe manifestation of thyroid eye disease
- Intervention
- Teprotumumab (IGF-1R inhibitor)
Primary outcomes
Early functional improvement in visual acuity/optic nerve function; Structural improvement on imaging of the optic nerve